1. Home
  2. LEU vs IDYA Comparison

LEU vs IDYA Comparison

Compare LEU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centrus Energy Corp.

LEU

Centrus Energy Corp.

HOLD

Current Price

$172.21

Market Cap

3.2B

Sector

Industrials

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$30.66

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEU
IDYA
Founded
1998
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
LEU
IDYA
Price
$172.21
$30.66
Analyst Decision
Buy
Strong Buy
Analyst Count
12
16
Target Price
$255.55
$52.86
AVG Volume (30 Days)
823.2K
1.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.90
EPS
0.45
N/A
Revenue
$193,000,000.00
$218,710,000.00
Revenue This Year
$3.76
N/A
Revenue Next Year
$6.04
$201.05
P/E Ratio
$367.71
N/A
Revenue Growth
N/A
3024.43
52 Week Low
$144.65
$20.50
52 Week High
$464.00
$39.28

Technical Indicators

Market Signals
Indicator
LEU
IDYA
Relative Strength Index (RSI) 47.76 57.36
Support Level $164.28 $29.51
Resistance Level $210.85 $31.51
Average True Range (ATR) 13.71 1.58
MACD 0.45 0.28
Stochastic Oscillator 45.74 80.74

Price Performance

Historical Comparison
LEU
IDYA

About LEU Centrus Energy Corp.

Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: